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Phosphatidylinositol 3-Kinase and Xanthine Oxidase Regulate
Nitric Oxide and Reactive Oxygen Species Productions by
Apoptotic Lymphocyte Microparticles in Endothelial Cells1
H. Ahmed Mostefai,2* Abdelali Agouni,2* Nunzia Carusio,* M. Letizia Mastronardi,*
Christophe Heymes,† Daniel Henrion,* Ramaroson Andriantsitohaina,*
and M. Carmen Martinez3*
Microparticles (MPs) are membrane vesicles released during cell activation and apoptosis. We have previously shown that MPs
from apoptotic T cells induce endothelial dysfunction, but the mechanisms implicated are not completely elucidated. In this study,
we dissect the pathways involved in endothelial cells with respect to both NO and reactive oxygen species (ROS). Incubation of
endothelial cells with MPs decreased NO production that was associated with overexpression and phosphorylation of endothelial
NO synthase (eNOS). Also, MPs enhanced expression of caveolin-1 and decreased its phosphorylation. Microparticles enhanced
ROS by a mechanism sensitive to xanthine oxidase and P-IB inhibitors. PI3K inhibition reduced the effects of MPs on eNOS,
but not on caveolin-1, whereas it enhanced the effects of MPs on ROS production. Microparticles stimulated ERK1/2 phosphor-
ylation via a PI3K-depedent mechanism. Inhibition of MEK reversed eNOS phosphorylation but had no effect on ROS production
induced by MPs. In vivo injection of MPs in mice impaired endothelial function. In summary, MPs activate pathways related to
NO and ROS productions through PI3K, xanthine oxidase, and NF-B pathways. These data underscore the pleiotropic effects of
MPs on NO and ROS, leading to an increase oxidative stress that may account for the deleterious effects of MPs on endothelial
function. The Journal of Immunology, 2008, 180: 5028–5035.
M icroparticles (MPs)4 are vesicles shed from the bleb-bing plasma membrane of various cell types, such asplatelets, T and B cells, monocytes, and endothelial
cells during activation by agonists, shear stress, or apoptosis (1, 2).
MPs constitute a heterogeneous population, differing in cellular
origin, number, size, antigenic composition, and functional prop-
erties (3). MPs bear cell surface proteins and the cytoplasmic com-
ponent of the original cell and exhibit negatively charged phos-
pholipids such as phosphatidylserine, and tissue factor (3, 4),
accounting for their procoagulant character and proinflammatory
properties, including alteration of vascular function (3, 4). MPs
may transfer bioactive molecules to other cells, different than those
from which they have been produced, thereby stimulating cells to
produce cytokines, cell adhesion molecules, growth factors and
tissue factor, and modulate endothelial functions (3). However, the
mechanisms involved in the effects produced by MPs are not fully
elucidated.
Elevated levels of circulating MPs have been detected in patho-
logical states (5–10) associated with vascular dysfunction, includ-
ing decrease of endothelium-dependent vasodilatation and/or al-
teration of responsiveness of vascular smooth muscle to
vasoconstrictor stimuli. Because MPs usually accumulate in areas
of disordered blood flow (1), the enhanced level of MPs may have
pathological consequences. Besides, the above effects of MPs are
related to their components, which depend on cell origin and on
stimuli used to generate them (11, 12). Thus, in previous studies,
we have shown that MPs generated from activated/apoptotic lym-
phocytes induced cell differentiation and NO production by a mor-
phogen-dependent mechanism (12, 13). In contrast, when MPs
were produced from apoptotic lymphocytes, they did not bear mor-
phogen, resulting in a lack of cell differentiation (12) and they
induced vascular dysfunction (8, 14). To date, little is known about
the effects of MPs on the function of cells that form the vessel wall,
such as endothelial cells, which are known to play a crucial role in
the regulation of vasomotricity and in inflammation. The endothe-
lium can release relaxant factors, including NO, prostacyclin, and
endothelium-derived hyperpolarizing factor. A change in the abil-
ity of endothelium to release these factors can lead to the devel-
opment of cardiovascular and/or inflammatory diseases. Further-
more, endothelial function is usually defined as NO production
and/or bioavailability. It is well-established that endothelium-de-
rived NO undergoes a very rapid reaction with superoxide anion
(O
2
.), thereby reducing NO bioavailability (15). Thus, increased
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oxidative stress impairs endothelial function, promoting inflam-
matory diseases including hypercholesterolemia, atherosclerosis,
and hypertension. MPs can affect endothelial function by altering
the balance between NO and reactive oxygen species (ROS) pro-
duction and release. In this way, it has been reported that MPs
decrease endothelial NO-dependent relaxation (eNOS) expression
(8) and enhance ROS production (16, 17).
Recently, we have shown that MPs from apoptotic T cells in-
duce endothelial dysfunction through the alteration of NO and
prostacyclin pathways (8), but the molecular mechanisms impli-
cated are not completely elucidated. The present study was de-
signed to investigate the signaling pathways of these MPs in en-
dothelial cells with respect to both NO pathway and ROS
production.
Materials and Methods
MP production
The human lymphoid CEM T cell line was used for MP production. Cells
were seeded at 106 cells/ml and cultured in serum-free X-VIVO 15 medium
(Cambrex). MPs were produced as previously described (12). Briefly, cells
were treated with actinomycin D (0.5 g/ml; Sigma-Aldrich) for 24 h.
Supernatant was obtained by centrifugation at 750 g for 15 min, and then
at 1,500  g for 5 min to remove cells and large debris, respectively. MPs
from the supernatant were washed after three centrifugation steps (45 min
at 14,000  g) and recovered in 400 l of NaCl 0.9%. Last washing
medium was used as control. The determination of the amount of MPs was
conducted by measuring MP-associated proteins using the DC Protein As-
say (Bio-Rad). MPs were used at 10 g/ml medium. Ten micrograms of
MPs correspond to 1,330  312  103 MPs. This concentration of lym-
phocyte MPs (0–2,000  103 MPs/ml plasma) is found in plasma from
patients undergoing carotid endarterectomy (18). MPs isolated from at least
four independent preparations were analyzed for each experimental
condition.
Cell culture
Human endothelial cell line (Eahy 926) was maintained in culture in me-
dium culture (DMEM, Ham’s F-12 1:1 (Cambrex), 1% L-glutamine, 1%
hypoxanthine/aminopterin/thymidine, 1% nonessential amino acids, 1%
sodium pyruvate and 1% streptomycin/penicillin) supplemented with 10%
of FBS (Invitrogen Life Technologies). Cells were grown for 24 h in the
absence or presence of 10 g/ml MPs after preincubation with or without
inhibitors (PI3K inhibitor, LY294002 (20 M; Calbiochem); MEK inhib-
itor U0126 (2 M; Calbiochem); NOS inhibitor, nitro-L-arginine (L-NA,
100 M; Sigma-Aldrich); inhibitor of IB- phosphorylation, Bay 11-
7082 (Bay, 7.5 M; BioMol Research); xanthine oxidase inhibitor, allo-
purinol (50 M; Sigma-Aldrich); NADPH oxidase inhibitor, apocynin
(100 M; Sigma-Aldrich); mitochondrial inhibitor, rotenone (10 M; Sig-
ma-Aldrich); or with the superoxide dismutase mimetic, manganese(III)
tetrakis (1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP 100
M; Calbiochem). MPs and all agents were used at concentrations at which
no cytotoxicity was observed, as deduced from trypan blue exclusion.
NO spin trapping and electronic paramagnetic resonance
(EPR) studies
The detection of NO production was performed using the technique with
Fe2 diethyldithiocarbamate (DETC; Sigma-Aldrich) as spin trap. Briefly,
after 24 h of MP treatment, cells were stimulated with either vehicle or
bradykinin (20 M; Sigma-Aldrich) for 45 min at 37°C. Then, the medium
was replaced with 250 l of Krebs solution, and then treated with 250 l
of colloid Fe(DETC)2 and incubated for 45 min at 37°C. NO detection was
measured in situ by EPR. Values are expressed in units per microgram per
microliter of endothelial cell proteins.
NO measurement was performed on a table-top x-band spectrometer
Miniscope (MS200; Magnettech). Recordings were made at 77°K, using a
Dewar flask. Instrument settings were 10 mW of microwave power, 1 mT
of amplitude modulation, 100 kHz of modulation frequency, 150 s of
sweep time and five scans. Signals were quantified by measuring the total
amplitude, after the correction of baseline as previously described (14).
The quantitative measurement of the NO-Fe(DETC)2 signal amplitude was
reported to the relative units for protein concentration (amplitude per mi-
crogram per microliter).
Nitrite and nitrate measurement by Griess assay
The production of NO was also quantified by measuring the released NO
metabolites (nitrite and nitrates) with Griess reagent (Promega). The cul-
ture medium samples were collected from control and MP-treated cells and
prepared cell-free by centrifugation. The medium was processed according
to the manufacturer’s protocol.
ROS measurement by dihydroethidine (DHE) staining
After incubation of endothelial cells with MPs at 10 g of proteins/ml for
24 h in absence or presence of inhibitors, they were washed three times
with phosphate buffer salt solution, and then incubated with the oxidative
fluorescent dye DHE (3 M; Sigma-Aldrich). Fluorescence (at 620 nm)
was measured and the number of DHE-positive cells after treatment with
MPs was measured by flow cytometry (Beckman Coulter). This method
allows the determination of labeled-positive cells (19). Thus, if the number
of positive cells increases with the treatment, that means that fluorescence
of these cells is enhanced as well. Fluorescent-positive cells were deter-
mined by flow cytometry.
In another set of experiments, aortae from male Swiss mice (8–10 wk
old) were treated in vitro with MPs and in situ production of O2. in the
vessel wall was evaluated with DHE as previously described (9). After
washing, vessel sections were mounted on glass slides. A Solamere con-
focal instrument with a DLS-300 laser mounted on a Nikon Eclipse TE
2000-S inverted microscope was used for the optical sectioning of the
tissue. Digital image recording was performed using QED in vivo software.
All animal studies were conducted using approved institutional protocols.
Western blotting
After treatment, cells were homogenized and lysated. Proteins (20 g)
were separated on 10% SDS-PAGE. Blots were probed with anti-eNOS,
caveolin-1 (BD Biosciences), phospho-caveolin-1 Tyr14, phospho-eNOS
Ser1177, phospho-eNOS Thr495, phospho-ERK 1/2 (Cell Signaling), phos-
pho-IB- (U.S. Biological), and Akt (Santa Cruz Biotechnology) Abs. A
polyclonal rabbit anti-human -actin Ab (Sigma-Aldrich) was used at
1/5000 dilution for visualization of protein gel loading. Also, 20 g of MPs
were separated on 10% SDS-PAGE, and blots were probed with anti-
NADPH oxidase subunits NOX1 and NOX4 Abs. The membranes were
then washed at least three times in Tris-buffer solution containing 0.05%
Tween 20 and incubated for 1 h at room temperature with the appropriate
HRP-conjugated secondary Ab (Amersham Biosciences). The protein-Ab
complexes were detected by ECL plus (Amersham) according to the pro-
tocol of the manufacturer.
Akt knockdown by small-interfering RNA (siRNA) and transient
transfection
siRNA duplexes specific for human Akt and control nonsilencing siRNA
were obtained from Santa Cruz Biotechnology. Transient transfection of
Eahy 926 endothelial cells was done according to the manufacturer’s pro-
tocol. Briefly, cells were seeded in 6-well plates, grown for 24 h (60%
confluence), and then transiently transfected with 100 nM Akt-specific or
control siRNA using the transfection reagent provided. Medium was re-
placed 24 h later by fresh medium and cells were grown for an additional
24 h. Then, cells were treated with MPs and NO measurements were
performed.
Vascular reactivity
Swiss mice (8–10 wk old) were treated in vivo by i.v. injection into the tail
vein of MPs (10 g/ml) as previously described (13). After 24 h, aortic
rings were isolated and mounted on a wire myograph. Endothelium-de-
pendent vasodilatation was studied in aortas with functional endothelium
precontracted with U46619 (Sigma-Aldrich).
Data analysis
Data are represented as mean  SEM; n represents the number of expe-
riences. Statistical analysis was performed by a one-way ANOVA, Mann-
Whitney U, or ANOVA for repeated measures with a subsequent Bonfer-
roni post-hoc test. A value of p  0.05 was considered to be statistically
significant.
Results
MPs reduce NO production in endothelial cells
Both control and MP-treated cells exhibited an EPR feature of
signals derived from NO-Fe(DETC)2. The NO-Fe(DETC)2 EPR
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signal was significantly reduced in cells treated by MPs. Although
no significant difference was observed between the three concen-
trations of MPs used (5, 10, and 20 g/ml), the decrease in NO
production was greatest at 10 g/ml, and this concentration was
used for all further studies. In addition, the NO-Fe(DETC)2 EPR
signal results for NOS activation as demonstrated by the abroga-
tion of the signal in the presence of the NO inhibitor, L-NA (Fig.
1A). To further demonstrate that the NO-Fe(DETC)2 EPR signal
reflects NO generation from endothelial cells, nitrite and nitrate,
both main metabolites of NO, were determined by Griess assay. As
FIGURE 1. MP treatment decreases NO production in endothelial cells. A, Quantification of the amplitude of the NO-Fe(DETC)2 complex signal in
human endothelial Eahy 926 cells. Cells were incubated for 24 h in the presence of either vehicle (CTL), 5, 10, or 20 g/ml MPs, or in the presence of
10 g/ml MPs plus the NO synthase inhibitor (L-NA, 100 M). B, Quantification of nitrite and nitrate productions in human endothelial Eahy cells. Cells
were incubated for 24 h in the presence of either vehicle (CTL) or MPs (10 g/ml). Supernatants were collected and assayed for nitrite and nitrate
production. C, Quantification of the amplitude of the NO-Fe(DETC)2 complex signal in human endothelial Eahy 926 control cells (CTL), 10 g/ml MP
alone, or in the presence of PI3K inhibitor LY294002 (LY, 20 M) or MEK inhibitor U0126 (10 M) and MPs (MPs LY or MPs U0126, respectively).
After 24 h, cells were incubated without or with bradykinin (BK, 20 M for 45 min) and in situ NO production was determined by EPR. D, Quantification
of the amplitude of the NO-Fe(DETC)2 complex signal in either control cells (CTL), 10 g/ml MP- or MPs  siRNA of the Akt-treated human endothelial
Eahy 926. Insert, Western blot for Akt expression in the control (lane 1), siRNA scrambled-(lane 2), or Akt siRNA (lane 3)-treated endothelial cells. Values
are expressed in units of amplitude per microgram per microliter of proteins of samples. The results are expressed as mean  SEM of five independent
experiments; , p  0.05, , p  0.01, , p  0.001 vs their respective CTL; †, p  0.05, ††, p  0.01 vs MPs alone.
FIGURE 2. Regulation of NO pathway by MPs: involvement of PI3K. Endothelial cells were incubated for 24 h with either vehicle (CTL), 10 g/ml
MP alone, PI3K inhibitor LY294002 (LY, 20 M) alone or plus MPs (MPs  LY). Twenty micrograms of proteins were subjected to 10% SDS-PAGE
and analyzed by Western blotting using Abs raised against: eNOS (A), phospho-eNOS Ser1177 (B), phospho-eNOS Thr495 (C), caveolin-1 (E), or phospho-
caveolin-1 Tyr14 (F). D, Phosphorylation level of eNOS at Ser1177 and Thr495. Quantitation of immunoblots was done by densitometric analysis. -actin
control was included. Data are representative of four separate blots, and the densitometry values are expressed in arbitrary units (AU) as mean  SEM.
, p  0.05; , p  0.01 vs CTL; †, p  0.05; ††, p  0.01 vs MP alone.
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shown in Fig. 1B, MP treatment reduced the nitrite/nitrate concen-
tration. Moreover, NO production was significantly reduced in
cells treated with MPs as compared with nontreated cells, and this
in the absence or in the presence of bradykinin (Fig. 1C). The
MP-induced NO decrease was almost completely reversed when
cells were incubated in the presence of the selective PI3K inhibitor
LY294002. Also, incubation with the MEK inhibitor U0126 par-
tially reversed the decrease of NO induced by MPs (Fig. 1C). It
should be noted that both inhibitors alone did not modify NO re-
lease from endothelial cells (data not shown). Furthermore, silenc-
ing Akt signaling using siRNA to Akt reversed MP-induced NO
decrease (Fig. 1D). Taken together, these data demonstrate that the
PI3K/Akt and MAPK pathways play a major role in the decrease
of NO induced by MPs.
Involvement of PI3K pathway in the regulation of enzymes
linked to NO production by MPs
We examined its probable implication in MP effects on endothelial
cells. Thus, we studied eNOS and caveolin-1 pathways with re-
spect to their possible regulation by PI3K using the inhibitor
LY294002. As shown in Fig. 2A, MP treatment increased eNOS
expression. Furthermore, eNOS phosphorylation either on its ac-
tivator (Ser1177) or inhibitor (Thr495) site was markedly enhanced
(Fig. 2, B and C) by MP treatment. However, the phosphorylation
on the inhibitor site was significantly greater (Fig. 2D). Interest-
ingly, the blockade of PI3K almost suppressed the effect of MPs on
both expression and phosphorylation of eNOS (Fig. 2, A and C).
Caveolin-1 plays a key role in negative regulation of eNOS
activity at the level of caveolae (20). As shown in Fig. 2E, MP
treatment increased caveolin-1 expression. However, caveolin-1
phosphorylation on Tyr14 was markedly reduced by MP treatment
(Fig. 2F). Interestingly, the inhibitor LY294002 had no effect on
the capacity of MPs to increase caveolin-1 expression (Fig. 2E) or
to decrease its phosphorylation (Fig. 2F).
Taken together, these data indicate that MPs regulate eNOS ac-
tivity, mainly via PI3K, by acting on its expression and phosphor-
ylation. In addition, MPs modulate caveolin-1 expression and ac-
tivity in a PI3K-independent manner.
Involvement of MAPK pathway in the regulation of enzymes
linked to NO production by MPs
The ERK 1/2 MAPK pathway may play a role in the effects of MPs
on endothelial cells. Indeed, we investigated the implication of this
pathway using the MEK inhibitor U0126. As shown in Fig. 3A,
blockade of MEK did not modify the effect of MPs on the expres-
sion of eNOS. However, it almost suppressed MP-induced phos-
phorylation of eNOS on both Ser1177 and Thr495 (Fig. 3, B and C),
to the same extent as the PI3K blockade shown above (Fig. 2, B
and C). As obtained with LY294002, the MEK silencing by U0126
had neither effect on the enhancement of caveolin-1 expression nor
FIGURE 3. Regulation of NO path-
way by MPs: involvement of ERK 1/2
MAPK. Endothelial cells were incu-
bated for 24 h with either vehicle
(CTL), 10 g/ml MP alone, MEK in-
hibitor U0126 (U, 10M) alone or plus
MPs (MPs  U). Twenty micrograms
of proteins were subjected to 10%
SDS-PAGE and analyzed by Western
blotting using Abs raised against:
eNOS (A), phospho-eNOS Ser1177 (B),
phospho-eNOS Thr495 (C), caveolin-1
(D), or phospho-caveolin-1 Tyr14 (E).
Immunoblots were quantified by densito-
metric analysis. -actin control was in-
cluded. Data are representative of four
separate blots, and the densitometry val-
ues are expressed in arbitrary units
(AU) as mean SEM. , p 0.05; ,
p 0.01 vs CTL; †, p 0.05; ††, p
0.01 vs MPs alone.
FIGURE 4. MPs induce ERK 1/2 phosphorylation. Endothelial cells were incubated for 24 h with either vehicle (CTL), 10 g/ml MPs alone, MEK
inhibitor U0126 (U, 10 M) alone or plus MPs (MPs  U) (A), PI3K inhibitor LY294002 (LY, 20 M) alone or plus MPs (MPs  LY) (B). Twenty
micrograms of proteins were subjected to 10% SDS-PAGE and analyzed by Western blotting, using Abs raised against phospho-ERK 1/2. Immunoblots
were quantified by densitometric analysis. -actin control was included. Data are representative of four separate blots, and the densitometry values are
expressed in arbitrary units (AU) as mean  SEM. , p  0.05 vs CTL; †, p  0.05 vs MPs alone.
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on the reduction of its phosphorylation upon MP treatment (Fig. 3,
D and E). Taken together, these data show that both LY294002
and MEK inhibitor U0126 had a similar suppressive effect on MP-
induced eNOS phosphorylation.
PI3K and MEK inhibition reduce MP-induced ERK1/2
phosphorylation
As shown in Fig. 4, the incubation of cells with MPs significantly
enhanced ERK 1/2 MAPK phosphorylation. As expected, the
U0126 treatment completely suppressed MP-induced phosphory-
lation of ERK (Fig. 4A). Interestingly, PI3K inhibitor partially sup-
pressed the MP-induced phosphorylation of ERK 1/2 (Fig. 4B).
These findings suggest a cross-talk between the PI3K and MAPK
pathways, PI3K being upstream of ERK 1/2 phosphorylation.
NF-B is involved in the effects of MPs
NF-B is a transcription factor that is complexed with IB- and
- in the cell cytoplasm, which are selectively phosphorylated,
ubiquinated, and degraded, leading to NF-B translocation. Phos-
phorylation of IB- is known to result in the activation of NF-B
and to allow its translocation to the nucleus. Because NF-B ac-
tivation might regulate increase of several protein expressions, we
have studied this pathway using an inhibitor of the phosphoryla-
tion of IB-, Bay. This inhibitor completely reversed the increase
in eNOS (Fig. 5A) and caveolin-1 (Fig. 5B) expressions induced by
MP treatment. In addition, although MPs did not affect the level of
phosphorylation of IB-, as expected, Bay decreases its phos-
phorylation (Fig. 5C).
MPs enhance ROS production in endothelial cells and mice
aortas
ROS play a well-documented role in endothelial dysfunction, thus
we investigated the possible involvement of oxidative stress in MP
effects in endothelial cells and the vascular wall. First, we evalu-
ated the production of ROS in endothelial cells after MP treatment.
The percentage of DHE-positive cells determined by flow cytom-
etry was greater by up to 20% in MP-treated cells vs control cells
(Fig. 6A). In contrast with NO, the PI3K inhibition potentiated the
MP-induced increase of ROS production (Fig. 6A), suggesting a
negative control of PI3K pathway on MP-induced ROS produc-
tion. In addition, MEK inhibition had no effect on the MP-induced
increase of ROS production (Fig. 6A), indicating that MP effects
on ROS production are ERK 1/2 independent. To determine the
sources of ROS production, cells were incubated in the presence of
inhibitors of either NADPH oxidase (apocynin), mitochondrial
complex I (rotenone), NO synthase (L-NA), or xanthine oxidase
(allopurinol) and O2. production was evaluated. ROS generation
was independent of NADPH oxidase, mitochondrial complex I ac-
tivity, or NO synthase (Fig. 6A). By contrast to other inhibitors,
allopurinol blunted the increase of DHE-positive cells induced by
FIGURE 5. The NF-B pathway is involved in the MP effects on endothelial cells. Human Eahy endothelial cells were treated for 24 h with either
medium (CTL) or 10 g/ml MPs in absence or in presence of the inhibitor of IB phosphorylation, Bay 11-7082 (7.5 M). Twenty micrograms of proteins
were subjected to 10% SDS-PAGE and analyzed by Western blotting using Abs raised against: eNOS (A), caveolin-1 (Cav; B), or P-IB- (C). Immu-
noblots were quantified by densitometric analysis. -actin control was included. Data are representative of four separate blots, and the densitometry values
are expressed in arbitrary units (AU) as mean  SEM. , p  0.05 vs CTL; †, p  0.05 vs MPs alone.
FIGURE 6. Mechanisms involved in the increase of ROS induced by
MPs in endothelial cells. A, Measurement of ROS production in endothelial
cells. Cells were treated for 45 min with LY294002 (LY, 20 M), U0126
(U, 10 M), apocynin (100 M), rotenone (10 M), L-NA (100 M),
allopurinol (50 M), Bay (7.5 M) or MnTMPyP (100 M) and then with
10 g/ml MPs for 24 h. After this, 30-min incubation with the fluorescent
dye DHE (3 M) was performed and the percentage of fluorescent-positive
cells was determined by flow cytometry. The results are expressed as
mean  SEM of five independent experiments. , p  0.05; , p  0.01;
, p  0.001 vs CTL; †, p  0.05 vs MPs alone. B, Twenty micrograms
of MPs proteins were subjected to 10% SDS-PAGE and analyzed by West-
ern blotting using Abs raised against NOX1 and NOX4. C, Endothelial
cells were treated for 24 h with MPs, and then NOX1 and NOX4 expres-
sion was detected by Western blotting. -actin control was included. D,
Detection of ROS production in the vascular wall. Mice aortas were treated
by 10 g/ml MPs or vehicle and then vessel sections were incubated 30
min with DHE and visualized by confocal microscopy. Results are repre-
sentative pictures of three independent experiments.
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MPs (Fig. 6A). It should be noted that the increase of ROS pro-
duction after rotenone treatment may be associated with the cyto-
toxicity of this drug on cells (21). Interestingly, the inhibitor of
phosphorylation of IB-, Bay, decreased the production of ROS
induced by MPs suggesting that the NF-B pathway is also
involved in ROS generation. As expected, the superoxide dis-
mutase mimetic MnTMPyP abolished MP-induced ROS pro-
duction (Fig. 6A).
Although MPs expressed NOX1 and NOX4 isoforms of
NADPH oxidase at their surface (Fig. 6B), they were not able to
either transfer these proteins to endothelial cells or to increase their
expression (Fig. 6C). Altogether, these data suggest that MPs en-
hanced ROS production via xanthine oxidase and NF-B
pathways.
In another set of experiences, we evaluated the in situ produc-
tion and the topographical distribution of ROS in mice aortas. Tis-
sue sections from vessels treated with MPs displayed a marked
increase in ethidium bromide fluorescence in the endothelium and
the medial layer (Fig. 6C), reflecting an increase in vascular wall
oxidative stress compared with the control.
MPs impair endothelial function
To evaluate the in vivo physiological significance of MPs in NO
production, MPs were injected into mice for 24 h. Under these
conditions, MPs decreased the acetylcholine-evoked endothelial
relaxation of precontracted vessels (Fig. 7).
Taken together, these findings suggest that endothelial dysfunc-
tion induced by MPs from apoptotic T cells is linked to the ca-
pacity of MPs to decrease NO and increase ROS in endothelial
cells.
Discussion
It is well-accepted that MPs generated under certain conditions
possess deleterious properties. Indeed, circulating MPs from pa-
tients with cardiovascular and/or inflammatory diseases are able to
impair endothelial function (6–8, 10). We have also reported that
MPs from cultured apoptotic T lymphocytes induce endothelial
dysfunction similar to that of circulating MPs (8). Although dif-
ferent mechanisms have been proposed to explain how MPs can
evoke endothelial dysfunction such as the modifications of the
eNOS expression (8) or the endothelial NO transduction pathway
(6), little is known about the mechanisms involved in the effects of
MPs on enzymes involved in NO generation.
In the present study, we demonstrate that MPs from apoptotic T
lymphocytes decreased the NO production and increased oxidative
stress in endothelial cells. These effects were associated with a
reduction of eNOS activity, which was dependent on PI3K, ERK
1/2, and NF-B pathways. The increase of ROS production that
was down-regulated by PI3K pathway involved xanthine oxidase
and NF-B pathways. Also, caveolin-1 expression and phosphor-
ylation were increased and reduced, respectively, by MP treatment,
these effects being independent of PI3K and ERK 1/2 cascade.
These data suggest that NO bioavailability is reduced during MP
treatment and can account for their capacity to promote endothelial
dysfunction, as shown in isolated aorta from mice treated
with MPs.
Endothelial production of NO was initially considered to be de-
pendent on increases in intracellular calcium and the binding of
calcium/calmodulin to eNOS. However, eNOS regulation is more
complex and is determined by a cascade of events, including
changes in eNOS mRNA and protein levels (22), association of
eNOS with regulatory proteins in the signaling complex (23),
changes in intracellular location of the enzyme (24), and phos-
phorylation of Ser, Thr, and Tyr residues (25). In line with this
concept, we have previously reported that MPs from apoptotic T
lymphocytes reduce eNOS expression in HUVECs, indicating that
these MPs are able to induce endothelial dysfunction (8). Here,
using the same MPs but Eahy cell line to avoid differences due to
donor of HUVECs, we found that NO production was reduced,
whereas eNOS expression was increased. The differential effect
induced by MPs on eNOS expression might be due to the use of
different cell types. Nevertheless, NO production was decreased in
both cell types, and caveolin-1 expression was increased, suggest-
ing that the cell model used in the present study is comparable to
the other endothelial cells previously used at least in terms of re-
duction of NO. In the present study, we also showed that MPs
enhanced eNOS phosphorylation on both activator and inhibitor
sites, but the eNOS phosphorylation on the latter was higher than
in the former, resulting in a decrease of NO produced. Altogether,
these results suggest that MPs evoke inhibition of eNOS activity
and contribute to the decrease of NO production and endothelial
dysfunction.
PI3K/Akt signal pathway is important for regulation of eNOS
expression and/or activity. It has been shown that the effects of
estrogen (26), VEGF (27) and shear stress (28) on eNOS pathway
involve PI3K/Akt signal pathway. In the present study, the inhi-
bition of PI3K by LY294002 prevented the up-regulation of eNOS
expression and phosphorylation in MP-treated endothelial cells, as
well as the reduction of NO. Also, silencing Akt expression with
siRNA to Akt abolished the reduction of NO induced by MPs.
Taken together, these findings indicate that MPs modify the eNOS
pathway through PI3K/Akt signal transduction.
Interestingly, MPs increased ERK 1/2 phosphorylation, which
was partially reversed in the presence of the PI3K inhibitor. In
addition, the present study using the MEK inhibitor U0126 clearly
showed the involvement of the MAPK pathway in the MP-induced
eNOS phosphorylation at both Ser1177 and Thr495 and in NO pro-
duction. Consistent with these results, ERK 1/2 has recently been
shown to be involved in estrogen-induced eNOS phosphorylation
(29). Thus, the findings of the present study suggest the existence
of cross-talk between the PI3K and MAPK pathways in the MP-
induced eNOS phosphorylation. Cross-talk between the PI3K and
MAPK pathways in vascular endothelial cells has been observed
with insulin-like growth factor-1 (30), but not with either vascular
endothelial growth factor (31) or sphingosine 1-phosphate (32)
stimulation. To our knowledge, the present work is the first to
describe the MP-mediated cross-talk between the MAPK and PI3K
pathways in endothelial cells.
The activity of eNOS is also regulated by subcellular localiza-
tion and/or protein-protein interactions. In this respect, eNOS ac-
tivity is inhibited when it interacts with caveolin-1 through the
caveolin-1-scaffolding domain (20). Data in the literature (33–35),
including our previous report (8), suggest that caveolin-1 could
FIGURE 7. MPs impair endothelial function. Acetylcholine-induced re-
laxation in control (CTL) and MP-injected mouse aorta. Results are ex-
pressed as a percentage of relaxation of U46619-induced precontraction.
, p  0.001 between the two curves.
5033The Journal of Immunology
 o
n
 O
ctober 11, 2010 
w
w
w
.jimmunol.org
D
ow
nloaded from
 
modify not only eNOS activity, but also its expression. In the
present study, we observed an increase of caveolin-1 expression in
MP-treated cells, which was associated with a decrease of eNOS
activity. Caveolin-1 is phosphorylated on Tyr14 by Src family ki-
nases (36–38), which leads to caveolae fission (39). Here, we re-
ported that MPs increased caveolin-1 expression and decreased its
phosphorylation on Tyr14 by a mechanism insensitive to PI3K and
MAPK inhibitors, while the NO production is decreased as re-
ported above. Collectively, these findings suggest that, in addition
to Thr495 phosphorylation of eNOS reflecting a decrease of eNOS
activity, the phosphorylation of caveolin-1 on Tyr14 may have a
determinant role in regulating caveolin-1, namely in caveolin-1/
eNOS interaction. However, further studies are necessary to deci-
pher the exact role of caveolin-1 phosphorylation in MP-mediated
regulation of NO pathway.
Accumulating evidence suggests that ROS play major roles in
the initiation and development of vascular diseases such as hyper-
tension, diabetes, or atherosclerosis, acting directly on vascular
cells (40). Indeed, ROS act by reducing the bioavailability of NO,
impairing endothelium-dependent vasodilatation and endothelial
cell growth, causing apoptosis, stimulating endothelial cell migra-
tion, and activating adhesion molecules and inflammatory reaction.
Here, we examined ROS production in both mouse aortic rings and
endothelial cells incubated with MPs. Interestingly, MPs increased
ROS production in both endothelial cells and mouse aorta, which
may be involved in the impairment of the endothelial function in
response to agonist and to flow in both conductance and resistance
arteries (8). ROS production in MP-treated endothelial cells was
enhanced in the presence of the PI3K inhibitor, but was not influ-
enced by MEK blockade, giving evidence that the PI3K, but not
the ERK 1/2, pathway partially and negatively regulates ROS gen-
eration. Among the main sources of ROS, NADPH and xanthine
oxidases play a major role in vascular cells (41), although eNOS
and complex I in mitochondria can also be involved in ROS pro-
duction. Here, we showed that among the pharmacological inhib-
itors used, inhibition of xanthine oxidase reduced the ability of
MPs to produce ROS. These results suggest that MPs exert their
effects on ROS production mainly via the xanthine oxidase path-
way. In accordance with our study, the inhibition of xanthine ox-
idase by allopurinol attenuates endothelial dysfunction associated
with diabetes and hypertension (42). In addition, MnTMPyP treat-
ment prevented the increase in ROS evoked by MPs, supporting a
role for endothelial cell O2. production as a mechanism underlying
the early reduction in NO bioavailability. Thus, inhibition of ROS
production through xanthine oxidase activity may represent a po-
tential therapeutic target in vascular pathologies associated with an
increase in the circulating level of deleterious MPs.
Finally, we have observed that mechanisms regulating MP ef-
fects on endothelial cells are controlled by the NF-B pathway.
Indeed, pharmacological inhibition of this pathway with Bay
blunted the enhancement of eNOS and caveolin-1 expression, as
well as, the reduction of ROS increase associated with MP
treatment.
In summary, MPs activate multiple pathways related to NO and
ROS production, mainly through PI3K. Besides, PI3K controls the
activation of ERK1/2 cascade, which counteracts the increase of
xanthine oxidase-derived ROS production by the former. Further-
more, the NF-B pathway regulates both NO and ROS production
associated with the effects of MPs. All these effects of MPs lead to
in vivo endothelial dysfunction into mice. Altogether, these data
underscore the pleiotropic effects of apoptotic MPs on NO and
ROS in endothelial cells leading to an increase oxidative stress in
the vessel wall. The latter may account for the deleterious effects
of MPs, resulting in endothelial dysfunction.
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